WENDY L DIXON Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for WENDY L DIXON.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of WENDY L DIXON. WENDY L DIXON is CMO & Pres, Global Marketing in BRISTOL MYERS SQUIBB CO ($BMY) and Director in INCYTE CORP ($INCY) and in bluebird bio, Inc. ($BLUE) and Director in bluebird bio, Inc. ($BLUE) and Director in Orexigen Therapeutics, Inc. ($OREX) and Director in Eleven Biotherapeutics, Inc. ($EBIO) and Director in Alkermes plc. ($ALKS) and Director in Voyager Therapeutics, Inc. ($VYGR) and Director in ARVINAS, INC. ($ARVN).
Latest Insider Trading Transactions of WENDY L DIXON
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ALKS, ARVN, BLUE, BMY, INCY, OREX, SESN, VYGR
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Apr 20 2021 | ALKS | Alkermes plc. | DIXON WENDY L | Director | Option Exercise | M | 14.60 | 25,000 | 365,000 | 0 | |
Apr 20 2021 | ALKS | Alkermes plc. | DIXON WENDY L | Director | Sell | S | 20.00 | 25,000 | 500,120 | 36,600 | 61.6 K to 36.6 K (-40.58 %) |
Apr 20 2021 | ALKS | Alkermes plc. | DIXON WENDY L | Director | Buy | M | 14.60 | 25,000 | 365,000 | 61,600 | 36.6 K to 61.6 K (+68.31 %) |
Apr 01 2021 | INCY | INCYTE CORP | DIXON WENDY L | Director | Grant | A | 81.27 | 225 | 18,286 | 14,878 | 14.7 K to 14.9 K (+1.54 %) |
Jan 15 2021 | ALKS | Alkermes plc. | DIXON WENDY L | Director | Option Exercise | M | 12.62 | 20,000 | 252,400 | 0 | |
Jan 15 2021 | ALKS | Alkermes plc. | DIXON WENDY L | Director | Option Exercise | M | 12.62 | 15,000 | 189,300 | 0 | |
Jan 15 2021 | ALKS | Alkermes plc. | DIXON WENDY L | Director | Option Exercise | M | 12.62 | 20,000 | 252,400 | 0 | |
Jan 15 2021 | ALKS | Alkermes plc. | DIXON WENDY L | Director | Buy | M | 12.62 | 20,000 | 252,400 | 36,600 | 16.6 K to 36.6 K (+120.48 %) |
Jan 15 2021 | ALKS | Alkermes plc. | DIXON WENDY L | Director | Option Exercise | M | 12.62 | 15,000 | 189,300 | 0 | |
Jan 15 2021 | ALKS | Alkermes plc. | DIXON WENDY L | Director | Buy | M | 12.62 | 15,000 | 189,300 | 16,600 | 1.6 K to 16.6 K (+937.50 %) |
Jan 15 2021 | ALKS | Alkermes plc. | DIXON WENDY L | Director | Buy | M | 12.62 | 20,000 | 252,400 | 36,600 | 16.6 K to 36.6 K (+120.48 %) |
Jan 15 2021 | ALKS | Alkermes plc. | DIXON WENDY L | Director | Buy | M | 12.62 | 15,000 | 189,300 | 16,600 | 1.6 K to 16.6 K (+937.50 %) |
Dec 04 2020 | ALKS | Alkermes plc. | DIXON WENDY L | Director | Option Exercise | A | 0.00 | 5,578 | 0 | 5,578 | |
Dec 04 2020 | ALKS | Alkermes plc. | DIXON WENDY L | Director | Option Exercise | A | 18.82 | 11,509 | 216,599 | 11,509 | |
Oct 01 2020 | INCY | INCYTE CORP | DIXON WENDY L | Director | Grant | A | 89.74 | 197 | 17,679 | 14,440 | 14.2 K to 14.4 K (+1.38 %) |
Aug 31 2020 | INCY | INCYTE CORP | DIXON WENDY L | Director | Option Exercise | M | 18.97 | 20,000 | 379,400 | 0 | |
Aug 31 2020 | INCY | INCYTE CORP | DIXON WENDY L | Director | Sell | S | 94.51 | 20,000 | 1,890,200 | 14,243 | 34.2 K to 14.2 K (-58.41 %) |
Aug 31 2020 | INCY | INCYTE CORP | DIXON WENDY L | Director | Buy | M | 18.97 | 20,000 | 379,400 | 34,243 | 14.2 K to 34.2 K (+140.42 %) |
Jul 01 2020 | ARVN | ARVINAS, INC. | DIXON WENDY L | Director | Option Exercise | A | 31.95 | 24,000 | 766,800 | 24,000 | |
Jul 01 2020 | INCY | INCYTE CORP | DIXON WENDY L | Director | Grant | A | 103.97 | 182 | 18,923 | 14,243 | 14.1 K to 14.2 K (+1.29 %) |
Jun 22 2020 | BLUE | bluebird bio, Inc. | DIXON WENDY L | Option Exercise | A | 64.09 | 3,000 | 192,270 | 3,000 | ||
Jun 22 2020 | BLUE | bluebird bio, Inc. | DIXON WENDY L | Grant | A | 0.00 | 1,500 | 0 | 5,653 | 4.2 K to 5.7 K (+36.12 %) | |
Jun 22 2020 | BLUE | bluebird bio, Inc. | DIXON WENDY L | Grant | A | 0.00 | 153 | 0 | 4,153 | 4 K to 4.2 K (+3.83 %) | |
Jun 05 2020 | VYGR | Voyager Therapeuti ... | DIXON WENDY L | Director | Option Exercise | A | 11.79 | 15,000 | 176,850 | 15,000 | |
May 28 2020 | INCY | INCYTE CORP | DIXON WENDY L | Director | Option Exercise | A | 98.68 | 10,514 | 1,037,522 | 10,514 | |
May 28 2020 | INCY | INCYTE CORP | DIXON WENDY L | Director | Grant | A | 0.00 | 1,282 | 0 | 14,061 | 12.8 K to 14.1 K (+10.03 %) |
May 22 2020 | ALKS | Alkermes plc. | DIXON WENDY L | Director | Option Exercise | A | 0.00 | 6,104 | 0 | 6,104 | |
May 22 2020 | ALKS | Alkermes plc. | DIXON WENDY L | Director | Option Exercise | A | 16.85 | 12,823 | 216,068 | 12,823 | |
Apr 02 2020 | INCY | INCYTE CORP | DIXON WENDY L | Director | Grant | A | 73.23 | 243 | 17,795 | 12,779 | 12.5 K to 12.8 K (+1.94 %) |
Jan 03 2020 | INCY | INCYTE CORP | DIXON WENDY L | Director | Grant | A | 87.32 | 196 | 17,115 | 12,536 | 12.3 K to 12.5 K (+1.59 %) |
Nov 08 2019 | INCY | INCYTE CORP | DIXON WENDY L | Director | Option Exercise | M | 12.46 | 18,334 | 228,442 | 0 | |
Nov 08 2019 | INCY | INCYTE CORP | DIXON WENDY L | Director | Option Exercise | M | 12.46 | 22,884 | 285,135 | 0 | |
Nov 08 2019 | INCY | INCYTE CORP | DIXON WENDY L | Director | Option Exercise | M | 12.46 | 1,540 | 19,188 | 22,884 | |
Nov 08 2019 | INCY | INCYTE CORP | DIXON WENDY L | Director | Option Exercise | M | 12.46 | 10,576 | 131,777 | 24,424 | |
Nov 08 2019 | INCY | INCYTE CORP | DIXON WENDY L | Director | Sell | S | 83.87 | 18,334 | 1,537,673 | 12,340 | 30.7 K to 12.3 K (-59.77 %) |
Nov 08 2019 | INCY | INCYTE CORP | DIXON WENDY L | Director | Buy | M | 12.46 | 18,334 | 228,442 | 30,674 | 12.3 K to 30.7 K (+148.57 %) |
Nov 08 2019 | INCY | INCYTE CORP | DIXON WENDY L | Director | Sell | S | 83.87 | 22,884 | 1,919,281 | 12,340 | 35.2 K to 12.3 K (-64.97 %) |
Nov 08 2019 | INCY | INCYTE CORP | DIXON WENDY L | Director | Buy | M | 12.46 | 22,884 | 285,135 | 35,224 | 12.3 K to 35.2 K (+185.45 %) |
Nov 08 2019 | INCY | INCYTE CORP | DIXON WENDY L | Director | Sell | S | 83.60 | 1,540 | 128,744 | 12,340 | 13.9 K to 12.3 K (-11.10 %) |
Nov 08 2019 | INCY | INCYTE CORP | DIXON WENDY L | Director | Buy | M | 12.46 | 1,540 | 19,188 | 13,880 | 12.3 K to 13.9 K (+12.48 %) |
Nov 08 2019 | INCY | INCYTE CORP | DIXON WENDY L | Director | Sell | S | 84.16 | 10,576 | 890,076 | 12,340 | 22.9 K to 12.3 K (-46.15 %) |
Nov 08 2019 | INCY | INCYTE CORP | DIXON WENDY L | Director | Buy | M | 12.46 | 10,576 | 131,777 | 22,916 | 12.3 K to 22.9 K (+85.71 %) |
Oct 02 2019 | INCY | INCYTE CORP | DIXON WENDY L | Director | Grant | A | 74.23 | 225 | 16,702 | 12,340 | 12.1 K to 12.3 K (+1.86 %) |
Jun 21 2019 | SESN | Sesen Bio, Inc. | DIXON WENDY L | Director | Option Exercise | A | 1.48 | 105,000 | 155,400 | 105,000 | |
Jun 17 2019 | VYGR | Voyager Therapeuti ... | DIXON WENDY L | Director | Option Exercise | A | 24.68 | 15,000 | 370,200 | 15,000 | |
Jun 10 2019 | BLUE | bluebird bio, Inc. | DIXON WENDY L | Director | Option Exercise | A | 122.01 | 4,000 | 488,040 | 4,000 | |
Jun 10 2019 | BLUE | bluebird bio, Inc. | DIXON WENDY L | Director | Grant | A | 0.00 | 1,000 | 0 | 4,000 | 3 K to 4 K (+33.33 %) |
May 23 2019 | ALKS | Alkermes plc. | DIXON WENDY L | Director | Option Exercise | A | 25.04 | 22,400 | 560,896 | 22,400 | |
Apr 29 2019 | INCY | INCYTE CORP | DIXON WENDY L | Director | Option Exercise | A | 75.03 | 12,472 | 935,774 | 12,472 | |
Apr 29 2019 | INCY | INCYTE CORP | DIXON WENDY L | Director | Grant | A | 0.00 | 1,520 | 0 | 11,907 | 10.4 K to 11.9 K (+14.63 %) |
Apr 02 2019 | INCY | INCYTE CORP | DIXON WENDY L | Director | Grant | A | 86.01 | 188 | 16,170 | 10,387 | 10.2 K to 10.4 K (+1.84 %) |
Oct 02 2018 | INCY | INCYTE CORP | DIXON WENDY L | Director | Grant | A | 69.08 | 235 | 16,234 | 9,944 | 9.7 K to 9.9 K (+2.42 %) |
Jun 22 2018 | BLUE | bluebird bio, Inc. | DIXON WENDY L | Director | Option Exercise | A | 183.10 | 4,000 | 732,400 | 4,000 | |
Jun 22 2018 | BLUE | bluebird bio, Inc. | DIXON WENDY L | Director | Grant | A | 0.00 | 1,000 | 0 | 3,000 | 2 K to 3 K (+50.00 %) |
Jun 18 2018 | VYGR | Voyager Therapeuti ... | DIXON WENDY L | Director | Option Exercise | A | 21.64 | 15,000 | 324,600 | 15,000 | |
Jun 14 2018 | EBIO | Sesen Bio, Inc. | DIXON WENDY L | Director | Option Exercise | A | 2.24 | 105,000 | 235,200 | 105,000 | |
May 24 2018 | ALKS | Alkermes plc. | DIXON WENDY L | Director | Option Exercise | A | 45.64 | 17,500 | 798,700 | 17,500 | |
May 03 2018 | INCY | INCYTE CORP | DIXON WENDY L | Director | Option Exercise | A | 60.85 | 15,000 | 912,750 | 15,000 | |
Apr 03 2018 | INCY | INCYTE CORP | DIXON WENDY L | Director | Grant | A | 83.33 | 195 | 16,249 | 9,467 | 9.3 K to 9.5 K (+2.10 %) |
Jun 30 2017 | VYGR | Voyager Therapeuti ... | DIXON WENDY L | Director | Option Exercise | A | 9.06 | 15,000 | 135,900 | 15,000 | |
Jun 12 2017 | BLUE | bluebird bio, Inc. | DIXON WENDY L | Director | Option Exercise | A | 111.00 | 4,000 | 444,000 | 4,000 | |
Jun 12 2017 | BLUE | bluebird bio, Inc. | DIXON WENDY L | Director | Grant | A | 0.00 | 1,000 | 0 | 2,000 | 1,000 to 2 K (+100.00 %) |
May 25 2017 | ALKS | Alkermes plc. | DIXON WENDY L | Director | Option Exercise | A | 58.25 | 14,200 | 827,150 | 14,200 | |
May 23 2017 | EBIO | Eleven Biotherapeu ... | DIXON WENDY L | Director | Option Exercise | A | 1.48 | 8,072 | 11,947 | 8,072 | |
Mar 31 2017 | INCY | INCYTE CORP | DIXON WENDY L | Director | Grant | A | 133.67 | 121 | 16,174 | 8,833 | 8.7 K to 8.8 K (+1.39 %) |
Jan 05 2017 | VYGR | Voyager Therapeuti ... | DIXON WENDY L | Director | Option Exercise | A | 11.97 | 30,000 | 359,100 | 30,000 | |
Dec 30 2016 | INCY | INCYTE CORP | DIXON WENDY L | Director | Grant | A | 100.27 | 162 | 16,244 | 8,712 | 8.6 K to 8.7 K (+1.89 %) |
Oct 04 2016 | INCY | INCYTE CORP | DIXON WENDY L | Director | Grant | A | 94.29 | 172 | 16,218 | 8,550 | 8.4 K to 8.6 K (+2.05 %) |
Jul 05 2016 | INCY | INCYTE CORP | DIXON WENDY L | Director | Grant | A | 79.98 | 203 | 16,236 | 8,378 | 8.2 K to 8.4 K (+2.48 %) |
Jul 05 2016 | INCY | INCYTE CORP | DIXON WENDY L | Director | Grant | A | 79.98 | 203 | 16,236 | 8,378 | 8.2 K to 8.4 K (+2.48 %) |
Jul 05 2016 | INCY | INCYTE CORP | DIXON WENDY L | Director | Grant | A | 79.98 | 203 | 16,236 | 8,378 | 8.2 K to 8.4 K (+2.48 %) |
Jun 10 2016 | EBIO | Eleven Biotherapeu ... | DIXON WENDY L | Director | Option Exercise | A | 1.83 | 8,072 | 14,772 | 8,072 | |
Jun 03 2016 | BLUE | bluebird bio, Inc. | DIXON WENDY L | Director | Option Exercise | A | 47.87 | 4,000 | 191,480 | 4,000 | |
Jun 03 2016 | BLUE | bluebird bio, Inc. | DIXON WENDY L | Director | Grant | A | 0.00 | 1,000 | 0 | 1,000 | 0 to 1,000 |
May 31 2016 | INCY | INCYTE CORP | DIXON WENDY L | Director | Option Exercise | A | 84.53 | 15,000 | 1,267,950 | 15,000 | |
May 26 2016 | ALKS | Alkermes plc. | DIXON WENDY L | Director | Option Exercise | A | 43.58 | 21,600 | 941,328 | 21,600 | |
Apr 01 2016 | INCY | INCYTE CORP | DIXON WENDY L | Director | Grant | A | 72.47 | 224 | 16,233 | 8,175 | 8 K to 8.2 K (+2.82 %) |
Dec 31 2015 | INCY | INCYTE CORP | DIXON WENDY L | Director | Grant | A | 108.45 | 149 | 16,159 | 7,951 | 7.8 K to 8 K (+1.91 %) |
Oct 02 2015 | INCY | INCYTE CORP | DIXON WENDY L | Director | Grant | A | 110.33 | 147 | 16,219 | 7,802 | 7.7 K to 7.8 K (+1.92 %) |
Jul 06 2015 | INCY | INCYTE CORP | DIXON WENDY L | Director | Grant | A | 104.21 | 155 | 16,153 | 7,655 | 7.5 K to 7.7 K (+2.07 %) |
Jun 18 2015 | EBIO | Eleven Biotherapeu ... | DIXON WENDY L | Director | Option Exercise | A | 2.68 | 8,072 | 21,633 | 8,072 | |
Jun 10 2015 | OREX | Orexigen Therapeut ... | DIXON WENDY L | Director | Option Exercise | A | 4.63 | 50,000 | 231,500 | 50,000 | |
Jun 08 2015 | BLUE | bluebird bio, Inc. | DIXON WENDY L | Director | Option Exercise | A | 184.98 | 7,500 | 1,387,350 | 7,500 | |
May 29 2015 | ALKS | Alkermes plc. | DIXON WENDY L | Director | Option Exercise | A | 60.57 | 16,000 | 969,120 | 16,000 | |
May 27 2015 | INCY | INCYTE CORP | DIXON WENDY L | Director | Option Exercise | A | 107.69 | 15,000 | 1,615,350 | 15,000 | |
May 24 2006 | BMY | BRISTOL MYERS SQUI ... | DIXON WENDY L | CMO & Pres, Global ... | Payment of Exercise | F | 24.16 | 3,396 | 82,047 | 87,003 | 90.4 K to 87 K (-3.76 %) |
Mar 09 2006 | BMY | BRISTOL MYERS SQUI ... | DIXON WENDY L | CMO & Pres, Global ... | Option Exercise | A | 22.73 | 37,145 | 844,306 | 37,145 | |
Mar 09 2006 | BMY | BRISTOL MYERS SQUI ... | DIXON WENDY L | CMO & Pres, Global ... | Payment of Exercise | F | 22.73 | 1,508 | 34,277 | 90,399 | 91.9 K to 90.4 K (-1.64 %) |
Mar 09 2006 | BMY | BRISTOL MYERS SQUI ... | DIXON WENDY L | CMO & Pres, Global ... | Grant | A | 22.73 | 5,107 | 116,082 | 91,907 | 86.8 K to 91.9 K (+5.88 %) |
Mar 09 2006 | BMY | BRISTOL MYERS SQUI ... | DIXON WENDY L | CMO & Pres, Global ... | Grant | A | 22.73 | 8,855 | 201,274 | 86,800 | 77.9 K to 86.8 K (+11.36 %) |
Dec 06 2005 | BMY | BRISTOL MYERS SQUI ... | DIXON WENDY L | CMO & Pres, Global ... | Payment of Exercise | F | 21.69 | 1,977 | 42,881 | 77,945 | 79.9 K to 77.9 K (-2.47 %) |
May 23 2005 | BMY | BRISTOL MYERS SQUI ... | DIXON WENDY L | CMO & Pres, Global ... | Payment of Exercise | F | 25.64 | 3,936 | 100,919 | 79,922 | 83.9 K to 79.9 K (-4.69 %) |
Mar 03 2005 | BMY | BRISTOL MYERS SQUI ... | DIXON WENDY L | CMO & Pres, Global ... | Option Exercise | A | 25.45 | 46,667 | 1,187,675 | 46,667 | |
Mar 03 2005 | BMY | BRISTOL MYERS SQUI ... | DIXON WENDY L | CMO & Pres, Global ... | Grant | A | 0.00 | 7,778 | 0 | 83,858 | 76.1 K to 83.9 K (+10.22 %) |
Dec 06 2004 | BMY | BRISTOL MYERS SQUI ... | DIXON WENDY L | CMO & Pres, Global ... | Payment of Exercise | F | 24.06 | 1,476 | 35,513 | 76,080 | 77.6 K to 76.1 K (-1.90 %) |
Mar 04 2004 | BMY | BRISTOL MYERS SQUI ... | DIXON WENDY L | CMO & Pres, Global ... | Option Exercise | A | 28.11 | 45,333 | 1,274,311 | 45,333 | |
Mar 04 2004 | BMY | BRISTOL MYERS SQUI ... | DIXON WENDY L | CMO & Pres, Global ... | Grant | A | 0.00 | 7,556 | 0 | 77,556 | 70 K to 77.6 K (+10.79 %) |
Sep 12 2003 | BMY | BRISTOL MYERS SQUI ... | DIXON WENDY L | CMO & Pres, Global ... | Grant | A | 0.00 | 10,000 | 0 | 70,000 | 60 K to 70 K (+16.67 %) |
Page: 1